Big Law

Gilead Sciences Invests $5.1 billion To Raise Stake In Galapagos

Gilead will partner with the Belgian-Dutch biotech firm to develop and commercialize its treatments for a ten-year period, the companies said on Sunday. The investment in Galapagos, which comes nearly four years after the firms partnered to develop a drug targeting inflammatory diseases, includes an upfront payment of $3.95 billion and a $1.1 billion equity investment from Gilead.

“Gilead gains exclusive access to all current and future compounds in Galapagos’ rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure,” Gilead Chief Executive Officer Daniel O’Day said in a statement.


    Leave a Review or Comment

    Your email address will not be published. Required fields are marked *

    Back to top button